SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a hot topic as NVIDIA's new autonomous driving platform sparks intense community debate over its potential challenge to Tesla's Full Self-Driving and robotaxi ambitions. Investors are weighing competitive pressures, including rising EV competition from BYD and renewed questions on core automotive performance, against the company's high valuation and long-term technological promises in AI and robotics.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is currently trending amid mixed sentiment, experiencing a price pullback while some speculate on its valuation and near-term growth catalysts, particularly concerning AI. The community is actively debating if its current price action is a healthy consolidation or a sign of deeper weakness, especially as it has recently lagged broader market rallies. Despite some positive reports on iPhone sales in international markets, many are looking for strong AI integration updates and future product optionality to drive renewed momentum.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is witnessing strong bullish momentum, driven by widespread community speculation around imminent regulatory clarity and significant institutional interest. Record ETF inflows and a perceived decoupling from Bitcoin's price action are fueling optimism, as the community eagerly discusses its potential for substantial future gains.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics, positioning it as the foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is experiencing strong upward momentum driven by the upcoming Investor Day, where the company will detail its updated business plan and 2026 financial outlook, alongside recent strategic announcements including a name change to Ondas Inc. and relocation of its headquarters. The community is actively discussing potential major contract announcements, technical breakouts, and the company's key position within the rapidly expanding autonomous drone and counter-drone defense sectors, fueling high expectations for future growth.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is a top trending topic following its CES 2026 keynote, which unveiled the next-generation Vera Rubin AI platform and new Alpamayo open-source models for autonomous vehicles. The community is actively discussing Rubin's reported early production and significant performance enhancements, alongside new partnerships reinforcing NVIDIA's expanding full-stack AI ecosystem across robotics and self-driving solutions, amidst ongoing debates about market valuation and future growth trajectories.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is experiencing a surge in attention following its collaboration with NVIDIA, integrating its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion platform ecosystem. This major validation from an industry leader is igniting strong bullish sentiment and driving widespread discussion about a potential short squeeze, especially given reported high short interest. The community is actively debating the long-term implications for AEVA within the competitive autonomous driving and LiDAR market, though some express caution regarding the timeline to full production.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is actively discussed following its announcement to integrate NVIDIA's next-gen Rubin AI platform, highlighting its critical role in the expanding AI infrastructure. This bullish news, coupled with recent revisions to GPU loan terms for improved liquidity, contrasts with community concerns regarding the company's substantial debt, insider selling activity, and potential project delays. The ongoing conversation reflects a highly divided sentiment as investors weigh long-term growth against immediate financial challenges and market volatility.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as escalating geopolitical tensions underscore the critical need for diversified rare earth supply chains, driving investor focus toward domestic producers. Recent reports of tightening Chinese export controls, coupled with strategic partnerships with the US Defense Department and Apple, highlight the company's pivotal role in establishing a secure mine-to-magnet ecosystem. The community is actively discussing MP's robust production growth and its long-term potential for Western rare earth independence, despite ongoing debates surrounding near-term profitability expectations.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is a major talking point following its impactful CES 2026 keynote, where it unveiled next-generation AI accelerators like the MI500 series and highlighted strategic partnerships in critical sectors such as space technology. The community is actively discussing AMD's aggressive push into AI and advanced computing, anticipating significant long-term growth and a re-evaluation of its market position within the competitive semiconductor industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today&#8217;s image-guided systems, the goal has remained the same: deliver enough energy to destroy tumors while sparing healthy tissue. What has changed, gradually, then suddenly, is the level of precision clinicians can bring to that task. A new generation of technologies is pushing radiation beyond its historical limits, opening therapeutic possibilities for patients who previously had few or no options.&nbsp;Alpha Tau Medical Ltd. (Nasdaq: DRTS) sits at the center of that ...

Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism

CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors&#8217; attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity&#8217;s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...

<ul class="summary-bullets"><li>MFN pricing extended nationwide through Medicaid and to future new medicines.</li><li>Steep direct-to-patient discounts rolled out via TrumpRx, including $35 insulin.</li><li>Additional pharma companies, including Johnson &amp; Johnson, are expected to ink similar deals next week.</li></ul><p>U.S. President Donald Trump on Friday announced nine new agreements with pharmaceutical companies to lower prescription drug prices for Americans to the lowest levels paid in other developed nations, under what the administration calls a “most-favored-nation” (MFN) pricing framework.</p><p>With these additions, 14 of the 17 pharmaceutical companies targeted by the administration in August have now signed on.</p><h2 class="st-heading-2"><strong>Big Pharma Roster Expands</strong></h2><p>The companies named in Friday’s agreements are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.</p><p>Trump said additional companies, including Johnson &amp; Johnson, are expected to announce similar agreements next week, as the administration continues to expand the program.</p><h2 class="st-heading-2"><strong>Medicaid Savings And Future Drug Pricing</strong></h2><p>The White House said the agreements apply to drugs used to treat an array of expensive, long-term conditions including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, HIV and certain cancers.</p><p>The administration said every state Medicaid program in the U.S. will benefit from MFN prices on products from the nine companies, which it estimates will save billions of dollars. The agreements also require MFN pricing for all new innovative medicines these companies bring to market.</p><p>Trump also floated the idea of calling a meeting with insurance companies to discuss further ways to lower healthcare costs, suggesting insurers could significantly reduce prices or face alternative approaches that would direct savings to consumers.</p><h2 class="st-heading-2"><strong>Deep Discounts Via TrumpRx</strong></h2><p>The administration said the companies are required to offer medicines at steep discounts off list prices when selling directly to American patients through TrumpRx, a government-backed direct-to-patient drug purchasing platform.</p><p>The administration said patients would see steep price cuts, citing examples such as Amgen’s Repatha at $239 versus&nbsp;list price of $573, Bristol Myers Squibb’s Reyataz at $217 versus $1,449, and Sanofi’s Plavix at $16 versus $756, alongside similar reductions for drugs from Gilead, GSK, Merck and Novartis. The administration also said Sanofi will list its insulin products on TrumpRx at $35&nbsp;for every&nbsp;month’s supply.</p><h2 class="st-heading-2"><strong>Drugmakers Pledge Domestic Investment</strong></h2><p>Trump said the participating companies have committed to invest at least $150 billion collectively in U.S. pharmaceutical manufacturing in the near term.</p><p>The administration also said several companies will donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve to strengthen emergency preparedness. GSK will contribute 98.8 kg of Albuterol, Bristol Myers Squibb will contribute tablets representing 6.5 tons of Apixaban, and Merck will contribute 3.5 tons of Ertapenem.</p><h2 class="st-heading-2"><strong>How Did Stocktwits React?</strong></h2><p>On Stocktwits, Health Care Select Sector SPDR Fund (XLV) showed 'bearish' retail sentiment amid 'high' message volume, while iShares Global Healthcare ETF (IXJ) saw 'bullish' sentiment with 'high' activity.</p><p><a href="https://stocktwits.com/symbol/XLV">XLV</a> and&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> have risen 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Trump announced his plan to lower drug prices would tie their cost to drug prices paid in foreign nations. (Photo by Andrew Harnik/Getty Images)

Trump Locks In Drug-Price Cuts With Roche, Novartis, Merck — More Big Pharma Deals Coming Next Week

The deals expand the pricing program to several drugmakers in exchange for temporary tariff relief.

Equity

Can Merck Successfully Steer Through the Upcoming Headwinds?

MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

<ul class="summary-bullets"><li>The talks follow the administration’s push to lower U.S. drug prices using trade and regulatory leverage.</li><li>Pfizer and AstraZeneca have already reached agreements, while several other major drugmakers are still weighing potential deals.</li><li>Novartis and Roche have highlighted U.S. investment and manufacturing commitments.</li></ul><p>Novartis' U.S.-listed stock rose on Wednesday as investors weighed reports of impending U.S. drug pricing deals tied to the company.</p><p>The announcement is expected as soon as Friday and could include Roche, though details are still being finalized and additional drugmakers may be added, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-17/novartis-roche-near-us-drug-price-deal-in-easing-of-swiss-trade-tensions">report</a> by Bloomberg.</p><h2 class="st-heading-2"><strong>Trump’s Push On Drug Prices</strong></h2><p>In August,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-turns-up-heat-on-big-pharma-ce-os-to-slash-drug-prices-within-60-days-but-retail-traders-don-t-flinch/chr3jLYRdGW">Trump sent letters to 17 pharmaceutical companies</a> demanding that they cut prices for U.S. government insurance programs and align domestic pricing more closely with what patients pay in other developed countries. The letters also called for companies to make medicines available through a Trump-branded direct-to-consumer platform and commit to not charging Americans more than foreign markets under a “most-favored-nation” pricing framework.</p><p>In exchange, companies were offered multiyear relief from threatened tariffs and some potential regulatory measures. The administration has said it is using trade policy as leverage to force price reductions, arguing that Americans pay more than triple what patients in other developed nations pay for the same drugs.</p><h2 class="st-heading-2"><strong>Who Has And Hasn’t Cut Deals</strong></h2><p>Pfizer and AstraZeneca have already struck agreements with the administration in recent months, but many other drugmakers are still on the sidelines. Companies such as AbbVie, Bristol-Myers Squibb, Gilead Sciences, Amgen, Johnson &amp; Johnson, Merck, Regeneron Pharmaceuticals and Sanofi have yet to announce any deals.</p><p>Novartis said in a statement to Bloomberg it is in talks with the administration and is committed to lowering U.S. drug costs while addressing price gaps with other developed countries. Meanwhile, Roche’s Genentech unit said it supports efforts to reduce U.S. prices while urging other nations to better reward biopharmaceutical innovation.</p><p>The White House cautioned that no deal is final. “Until officially announced by President Trump or the Administration, any reporting about potential dealmaking is speculation,” spokesman Kush Desai told the news outlet.</p><h2 class="st-heading-2"><strong>Manufacturing Commitments&nbsp;</strong></h2><p>Domestic manufacturing has played a central role in negotiations. Novartis has stepped up its U.S. footprint, with CEO Vas Narasimhan recently attending the opening of a new manufacturing facility in North Carolina alongside FDA Commissioner Marty Makary.</p><p>The company plans to invest $23 billion in the U.S. over the next five years and generate about 41% of its revenue from the market, led by drugs such as Entresto. Roche has also committed to expanding in the U.S., pledging $50 billion in investment and deriving nearly half of its revenue from the country, driven by treatments including Ocrevus and Tecentriq.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Novartis was ‘bearish’ with ‘low’ message volume, while Roche was ‘bullish’ amid ‘high’ message volume.</p><p>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/NVS">Novartis’ U.S.-listed shares</a> have risen 42%, while&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s U.S.-listed stock</a> has also gained 45% over the same period.</p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Current Price	$51.37
Prev Close	$51.45
Open	$51.29
Dividend Yield	2.45%
50-Day Moving Average	$47.19
Beta	0.32
Avg. Volume	2.45M
PE Ratio	29.98

52-Week High	$53.00
52-Week Low	$34.75
Market Capitalization	$283.41B
EPS (Annual)	$1.47
Price to Book	9.08
Revenue Per Employee	$665,306.28
Enterprise Value/EBITDA	N/A

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RHHBY News

RHHBYRoche Holdings AG ADR